Parmax Pharma Ltd issued a corrigendum for its July 2, 2026 EGM. The meeting will discuss a preferential issue of 21.45 lakh warrants for ₹7.83 crore. Corrections involve promoter status and a hyperlink.
Parmax Pharma Ltd: EGM Corrigendum and Preferential Issue Details
Parmax Pharma Ltd announced a corrigendum for its upcoming Extraordinary General Meeting (EGM) scheduled for July 2, 2026. The filing clarifies administrative details related to a preferential issue of equity shares and convertible warrants.
Reader Takeaway: Procedural EGM update; key preferential issue of 21.45 lakh warrants for ₹7.83 crore is central.
What just happened
Parmax Pharma Ltd has issued a corrigendum for its EGM notice originally dated June 9, 2026. The meeting, set for July 2, 2026, will address a preferential issue. The corrigendum makes minor administrative corrections.
Why this matters
This filing is crucial for understanding the details of a significant preferential issue. It involves the potential issuance of 21,45,145 warrants for a total consideration of ₹7.83 crore. This capital raise could impact the company's financials and ownership structure.
The backstory
The original notice for the EGM was issued on June 9, 2026. The preferential issue aims to raise capital through the issuance of warrants, which are convertible into equity shares.
What changes now
The corrigendum makes two specific changes: the promoter status of Ms. Sheetal Hiren Doshi is corrected to 'Promoter Group*', and a hyperlink for a certificate has been updated. These changes are administrative and do not affect the core aspects or validity of the original notice.
Risks to watch
Investors should monitor the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 compliance. The preferential issue may trigger an open offer, leading to potential changes in control and promoter classification.
Peer comparison
Information on peer capital raises or EGM-related preferential issues is not available in the filing.
Context metrics (time-bound)
- EGM Date: July 2, 2026
- Original Notice Date: June 9, 2026
- Total Warrants: 21,45,145
- Total Consideration: ₹7.83 crore (₹782.98 lakh)
What to track next
Shareholders should watch the outcome of the EGM and the subsequent open offer process, which will clarify the future ownership structure of Parmax Pharma Ltd.